Search

The U.S. Food and Drug Administration (FDA) has approved Nefecon delayed release capsules as the first fully FDA-approved treatment for primary immunoglobulin A nephropathy (IgAN), a kidney disease. Nefecon is designed to reduce the loss of kidney function in adults with IgAN at risk for disease progression. The FDA approval is based on a measure of kidney function and is not dependent on proteinuria levels. Nefecon has also been approved by China's National Medical Products Administration and has shown positive results in Chinese subpopulation analysis. This approval provides hope for the global IgAN community, and the treatment will be launched in China in the first quarter of 2024. [Extracted from the article]

A new report from researchers at North Sichuan Medical College in Nanchong, China explores the effects of chrysophanol (Chr), a compound found in rhubarb, on diabetic nephropathy (DN). DN is a complication of diabetes that increases the risk of diabetes-related mortality. The study found that Chr reduced oxidative stress and pyroptosis (a type of cell death) in mice with DN by activating the Keap1/Nrf2 pathway. These findings suggest that Chr may have potential therapeutic benefits for DN. [Extracted from the article]

A recent study conducted at Shanxi Bethune Hospital in China explored the effect of hydration therapy and nursing intervention on preventing contrast-induced nephropathy (CIN) after interventional treatment of lower extremity arteriosclerosis obliterans (ASO). The study involved 94 patients who underwent endovascular interventional therapy and were divided into two groups. The observation group received hydration therapy and nursing intervention, while the control group received routine nursing intervention. The results showed that hydration therapy and nursing intervention effectively prevented CIN, improved clinical outcomes, and resulted in higher patient satisfaction. The study suggests that this therapy should be promoted and applied in clinical settings. [Extracted from the article]

A recent study conducted by researchers at Mudanjiang Medical University in China has provided new insights into diabetic nephropathy, a chronic inflammatory disease that affects millions of diabetic patients worldwide. The study emphasizes the importance of early diagnosis and prevention in treating diabetic nephropathy, as renal damage becomes difficult to reverse once the patient enters the clinical proteinuria stage. The researchers highlight the role of ferroptosis, a type of programmed cell death characterized by iron-dependent lipid peroxidation and excessive ROS production, in the development of diabetic nephropathy. They suggest that understanding the regulatory mechanisms of ferroptosis and its relationship with inflammation can deepen our understanding of the pathogenesis of diabetic nephropathy and potentially lead to the development of new therapeutics targeting ferroptosis or inflammation-related regulatory mechanisms. [Extracted from the article]

A study conducted by researchers at Hebei Engineering University in China has found that transgelin-2 may serve as an early detection marker for diabetic nephropathy (DN), a complication of diabetes that can lead to chronic renal failure. The study involved collecting serum samples from DN patients and normal volunteers, as well as conducting experiments on mice and in vitro models. The researchers discovered that transgelin-2 was highly expressed in DN patients and correlated with blood sugar levels. They also found that transgelin-2 promoted inflammation and periostin levels, while suppressing E-cadherin levels, through STAT3 signaling via ANXA2. These findings suggest that transgelin-2 could be a potential target for early detection and treatment of DN. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Zhengzhou University in China has found that a combination of gut microbiota and clinical indicators can potentially be used to differentiate between idiopathic membranous nephropathy (IMN) and minimal change disease (MCD). Currently, the definitive diagnosis for these conditions relies on invasive renal biopsy, which can be limited in clinical practice. The study collected clinical data and stool samples from healthy individuals, IMN patients, and MCD patients, and used machine learning methods to construct a classifier that can differentiate between the two conditions. The research suggests that the gut microbiota may play a role in kidney injury and that the classifier combining gut microbiota and clinical indicators provides a noninvasive approach to identifying different types of kidney disease. [Extracted from the article]

A study conducted at Peking University Third Hospital in China examined the use of anti-phospholipase A2 receptor (anti-PLA2R) antibodies for diagnosing idiopathic membranous nephropathy (IMN). The study found that the optimal cutoff value for anti-PLA2R antibodies in diagnosing IMN was 2.5 RU/mL, which was lower than the value suggested by the manufacturer. The study also found a positive correlation between anti-PLA2R antibody levels and urinary protein levels, as well as a negative correlation with serum albumin levels in IMN patients. Additionally, the study showed that immunosuppressive therapy was associated with a higher remission rate in IMN patients. The researchers concluded that actively treating IMN can lead to better prognoses. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Nanjing Medical University in China explored the relationship between glomerular basement membrane (GBM) thickness and treatment response in patients with primary membranous nephropathy (PMN). The study found that patients with a higher level of GBM thickening at diagnosis had a lower probability of achieving complete remission (CR). GBM thickness was identified as an independent risk factor for CR, even after adjusting for other factors such as age, duration of PMN, and urinary protein excretion. These findings suggest that GBM thickness can predict treatment outcomes in PMN patients. [Extracted from the article]

Researchers at the Affiliated Hospital of Qingdao University in China have developed a preliminary nomogram model for predicting the relapse risk in patients with primary membranous nephropathy (PMN). The study collected data from 400 PMN patients who achieved remission and used Cox regression analysis to identify predictive factors for relapse. The model incorporates indicators such as hyperuricemia, high C-reactive protein levels, and treatment with calcineurin inhibitors. The model demonstrated good discrimination and calibration in predicting relapse probability. This research provides valuable insights for clinicians in managing and predicting relapse in PMN patients. [Extracted from the article]

A new report from Central South University in China discusses the relationship between iron metabolism and chronic inflammation in IgA nephropathy (IgAN), a common kidney disease in Asia. The researchers explain that the deposition of immune complexes in renal mesangial cells leads to chronic inflammation and kidney damage in IgAN. They also highlight the role of iron metabolism in the pathogenesis, progression, diagnosis, and prognosis of the disease. The review aims to explore the potential diagnostic and therapeutic significance of iron metabolism indicators in IgAN. [Extracted from the article]

Researchers from the University of Electronic Science and Technology of China have developed a prediction model for treatment failure in primary membranous nephropathy (PMN). The study collected information on clinical characteristics, laboratory test results, pathological examination, and treatment from patients diagnosed with PMN. The model identified PLA2R antibody, renal interstitial inflammation infiltration, and C3 deposition on immunofluorescence as the three independent risk factors for treatment failure in PMN. The researchers suggest that this prediction model could help identify patients at risk of treatment failure, although further improvement is needed. [Extracted from the article]

A new study conducted at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine in China has investigated the effects of Clerodendranthus spicatus Thunb. (CS) on hyperuricaemic nephropathy (HN). The study found that CS, a traditional Chinese medicinal herb, can reduce serum uric acid levels and improve renal function in HN. In both in vivo and in vitro experiments, CS inhibited the fibrotic process in renal cells, protected renal function, and showed potential as a treatment for HN. These findings provide valuable insights for the clinical application of CS in HN treatment. [Extracted from the article]

A recent study conducted by researchers from Shandong University in China explored the potential associations between plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and coagulation indexes in patients with primary membranous nephropathy (PMN). The study included 87 patients diagnosed with PMN and found that plasma PCSK9 levels were significantly higher in patients with PMN compared to healthy controls. The study also found positive correlations between PCSK9 levels and procoagulant clotting factors, as well as negative correlations with prothrombin time (PT). These findings provide new insights into the relationship between PCSK9 and hypercoagulability in PMN. [Extracted from the article]

A recent study conducted by researchers at North Sichuan Medical College in China aimed to develop a noninvasive method for differentiating between immunoglobulin A nephropathy (IgAN) and non-IgAN. The researchers used deep learning radiomics and clinical factors to create a combined nomogram model. The model was tested on a group of 120 patients with primary glomerular disease and showed strong discrimination between IgAN and non-IgAN. The researchers concluded that the combined nomogram model could accurately and noninvasively diagnose IgAN and assist physicians in developing treatment plans. [Extracted from the article]

A cohort study conducted by Nanjing University Medical School in China examined the prevalence, clinical features, and prognosis of anemia in patients with membranous nephropathy (MN). The study found that anemia in MN patients is primarily mild to moderate normocytic anemia. Acute renal tubular injury and clinical nutritional status were identified as independent risk factors for anemia. The study also observed differences in renal prognosis among anemia patients with different treatment outcomes. This research provides valuable insights into the understanding and management of anemia in MN patients. [Extracted from the article]

Researchers in China have conducted a cohort study to investigate the relationship between plasma D-dimer levels and the progression of kidney disease in IgA nephropathy (IgAN). The study involved 1818 patients with IgAN and found that higher plasma D-dimer levels were associated with an increased risk of kidney disease progression events. The researchers concluded that high plasma D-dimer levels may be a potential predictor of disease progression in IgAN. This research provides valuable insights into the understanding and management of IgAN. [Extracted from the article]

A recent report from the Second Affiliated Hospital of Xi'an Jiaotong University in China discusses the treatment of primary membranous nephropathy (pMN), the most common type of nephrotic syndrome in adults. The study compared the efficacy and safety of a low-dose multitarget regimen (LDMT) consisting of glucocorticoids, tacrolimus, and mycophenolate mofetil, with a regimen of prednisone plus intravenous cyclophosphamide (PC). The results showed that the LDMT regimen had a more favorable safety profile and non-inferior efficacy compared to the PC regimen. The study suggests that the LDMT regimen could be an alternative treatment option for patients with pMN. [Extracted from the article]

A study conducted at Guangdong Provincial People's Hospital in China investigated the clinicopathological characteristics and initial therapeutic effects of idiopathic membranous nephropathy (IMN) in elderly patients. The study included 67 elderly patients with biopsy-proven IMN, and the results showed that glomerular PLA2R and IgG4 antigen deposition were frequently detected in these patients. The study also found that early initial immunosuppressive therapy could achieve a higher urinary protein remission rate in high-risk elderly patients with severe proteinuria. The researchers concluded that individualized treatment regimens based on clinical and pathological characteristics are crucial for elderly patients with IMN. [Extracted from the article]

A recent study conducted in China compared the effectiveness of two different treatment regimens for patients with membranous nephropathy (MN) combined with focal and segmental glomerular sclerosis (FSGS) lesions. The study found that patients initially treated with calcineurin inhibitors (CNIs) had a higher risk of renal functional decline and a higher rate of relapse compared to those treated with cyclophosphamide (CTX) therapy. These findings suggest that CTX therapy may be more beneficial for patients with MN and FSGS lesions. Further research is needed to confirm these results and explore potential treatment options. [Extracted from the article]

A recent study conducted at the Affiliated Hospital of Hebei University of Engineering in China explored the role of long noncoding RNA taurine-up-regulated gene 1 (TUG1) in renal tubular fibrosis in experimental diabetic nephropathy (DN). The researchers found that TUG1 expression was downregulated in high glucose-treated kidney cells and that overexpression of TUG1 alleviated kidney injury and suppressed inflammation and fibrosis. The study also identified miR-145-5p and dual-specificity phosphatase 6 (DUSP6) as potential targets of TUG1. The findings suggest that TUG1 may have a protective effect against kidney injury in DN through the miR-145-5p/DUSP6 axis. [Extracted from the article]

A study conducted by researchers from Zhejiang Chinese Medical University in China investigated the mechanism of triptolide (TP) in podocyte injury in diabetic nephropathy (DN). DN is the most common microvascular complication of diabetes mellitus. The study found that TP improved renal function and histopathological injury in DN mice by activating the Nrf2/heme oxygenase-1 (HO-1) pathway and inhibiting the nod-like receptor (NLR) family pyrin domain containing 3 (NLRP3) inflammasome pathway. These findings suggest that TP may alleviate podocyte injury in DN by inhibiting oxidative stress and pyroptosis. [Extracted from the article]

A study conducted by researchers from Ningbo University in China explored the relationship between a gene polymorphism and the subclass of immunoglobulin G (IgG) in renal tissues for patients with idiopathic membranous nephropathy (IMN). The study aimed to predict the sensitivity of IMN patients to immunosuppressive therapy. The researchers found that the PLA2R gene polymorphism combined with the IgG subclass can be used to predict the response of IMN patients to immunosuppressive therapy. The study included 60 patients with IMN and was conducted at the First Affiliated Hospital of Ningbo University. [Extracted from the article]

Everest Medicines has announced that China's National Medical Products Administration (NMPA) has approved Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. This approval marks a significant milestone for IgAN treatment in China, where there is a high prevalence of the disease. Nefecon is the first-ever treatment for IgAN approved by the U.S. Food and Drug Administration and European Medicines Agency, and it has shown positive results in protecting renal function and reducing proteinuria and hematuria. The approval of Nefecon in China fills a gap in targeted treatment options for IgAN and provides new hope for patients in the nation. [Extracted from the article]

A recent report from researchers at the Third Hospital of Hebei Medical University in China discusses the progress made in understanding the role of autophagy in the development of diabetes nephropathy (DN), a common complication of diabetes and a leading cause of end-stage renal disease. The researchers highlight the complex nature of DN and its relationship to autophagy, oxidative stress, endoplasmic reticulum stress, inflammatory reactions, and the renin angiotensin aldosterone system. They also suggest that targeting the autophagy pathway to restore its activity may have a nephroprotective effect. This article provides a valuable overview of recent research on autophagy in the pathogenesis of DN. [Extracted from the article]

Everest Medicines, a partner of Calliditas Therapeutics, has announced that China's National Medical Products Administration (NMPA) has approved Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. This approval is significant as China has the highest prevalence of primary glomerular diseases in the world, with an estimated five million IgAN patients. Results from the Phase 3 NefIgArd trial showed that Nefecon had a greater treatment effect in the Chinese cohort compared to the global data set, with regards to kidney function, proteinuria, and microhematuria. This approval will trigger a milestone payment of five million USD to Calliditas. [Extracted from the article]

A recent report from the University of Electronic Science and Technology of China provides new insights into diabetic nephropathy (DN), the most common complication of diabetes. The researchers used various databases and analysis techniques to identify and validate key genes associated with DN. They found that CXCL6, CD48, C1QB, and COL6A3 may be key genes that promote the onset of DN and are closely related to kidney function and immune cell infiltration. This research contributes to a better understanding of the pathogenesis of DN and may facilitate individualized treatment for patients. [Extracted from the article]

A recent study conducted at the Second Affiliated Hospital of Nanchang University in China has explored the role of necroptosis, a form of programmed cell death, in diabetic nephropathy (DN). DN is a severe complication of diabetes and a leading cause of end-stage renal diseases. The researchers used machine learning and differential expression analysis to identify necroptosis-related genes and subtypes of DN. They developed a necroptosis-mediated diagnostic model for DN and investigated the immune landscape and inflammatory response associated with these subtypes. This research provides new insights into the relationship between necroptosis and DN, potentially leading to improved diagnostic and therapeutic strategies. [Extracted from the article]

A new report from the University of Jinan in China discusses research on diabetic nephropathy, a complication of diabetes that affects the kidneys. The researchers propose a deep learning algorithm to screen high-risk patients with diabetic nephropathy using retinal images. They use attentional mechanisms to improve the model's focus on lesion-prone regions of the images. The proposed model performs well in disease classification, with an accuracy of 91.68%, sensitivity of 89.99%, and specificity of 92.18%. The researchers conclude that the proposed model can provide reliable screening for high-risk patients with diabetic nephropathy. [Extracted from the article]

Keywords: Asia; China; Epidemiology; Health and Medicine; Kidney Diseases and Conditions; Nephrology; Nephropathy EN Asia China Epidemiology Health and Medicine Kidney Diseases and Conditions Nephrology Nephropathy 1080 1080 1 10/30/23 20231030 NES 231030 2023 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- New research on nephropathy is the subject of a new report. Asia, China, Epidemiology, Health and Medicine, Kidney Diseases and Conditions, Nephrology, Nephropathy. [Extracted from the article]

Keywords: Asia; China; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathy; Health and Medicine; Kidney Diseases and Conditions; Nephrology; Nephropathy; Nutritional and Metabolic Diseases and Conditions EN Asia China Diabetes Complications Diabetes Mellitus Diabetic Nephropathy Health and Medicine Kidney Diseases and Conditions Nephrology Nephropathy Nutritional and Metabolic Diseases and Conditions 939 939 1 07/17/23 20230717 NES 230717 2023 JUL 17 (NewsRx) -- By a News Reporter-Staff News Editor at Diabetes Week -- Investigators publish new report on diabetic nephropathy. Asia, China, Diabetes Complications, Diabetes Mellitus, Diabetic Nephropathy, Health and Medicine, Kidney Diseases and Conditions, Nephrology, Nephropathy, Nutritional and Metabolic Diseases and Conditions. [Extracted from the article]

Health and Medicine, Kidney Diseases and Conditions, Membranous Nephropathy, Nephrology, Nephropathy Keywords: Health and Medicine; Kidney Diseases and Conditions; Membranous Nephropathy; Nephrology; Nephropathy EN Health and Medicine Kidney Diseases and Conditions Membranous Nephropathy Nephrology Nephropathy 2023 FEB 10 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on membranous nephropathy is now available. [Extracted from the article]